Clinical trial
A Study of Recombinant Human Erythropoietin in Anemic Cancer Patients Undergoing…
NCT00144495 · Chugai Pharmaceutical, Industry · Completed
Key facts
| NCT number | NCT00144495 |
|---|---|
| Title | A Study of Recombinant Human Erythropoietin in Anemic Cancer Patients Undergoing Chemotherapy |
| Official title | A Multicenter, Open-Label Study of Recombinant Human Erythropoietin in Anemic Cancer Patients Undergoing Chemotherapy |
| Lead sponsor | Chugai Pharmaceutical, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Chemotherapy Induced Anemia |
| Intervention type | Drug |
| Interventions | recombinant human erythropoietin |
| Enrollment | 104 |
| Start date | Feb 1, 2004 |
| Primary completion | Nov 1, 2004 |
| Completion | May 1, 2005 |
| First posted | Sep 5, 2005 |
| Last update posted | Feb 2, 2009 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: